Benidipine Hydrochloride (Coniel) is a long-acting calcium channel blocker belonging to the dihydropyridine class of antihypertensive drugs, and is widely indicated for the treatment of hypertension and angina pectoris. By selectively inhibiting calcium ion influx across the cell membrane of vascular smooth muscle, this drug dilates peripheral blood vessels and coronary arteries, thereby lowering blood pressure and improving myocardial blood supply.
What are the Indications of Benidipine Hydrochloride (Coniel)?
Hypertension and Related Disorders
(1) Essential hypertension: It is indicated for the long-term management of mild to moderate hypertension in adults.(2) Renal parenchymal hypertension: It is especially suitable for hypertensive patients with renal impairment, as it exerts a certain renoprotective effect and can improve renal blood flow and glomerular filtration function.(3) Severe hypertension: Under the guidance of physicians, it may be used for the treatment of severe hypertension, and the usual dosage shall be adjusted according to the patient's condition.
Angina Pectoris
(1) Exertional angina pectoris: It can effectively reduce the frequency of angina attacks and improve exercise tolerance.(2) Mixed angina pectoris: It also exerts a relieving effect on angina pectoris that may occur both during physical exertion and at rest.(3) This drug shall be administered strictly under physician's prescription; self-medication and arbitrary dosage adjustment are prohibited.
Specifications and Characteristics of Benidipine Hydrochloride (Coniel)
Pharmaceutical Specifications
(1) Benidipine Hydrochloride Tablets are available in three specifications, all of which are film-coated tablets with a yellow appearance.(2) Benidipine Hydrochloride Tablets 2 mg: Each tablet contains 2 mg of benidipine hydrochloride, with a diameter of approximately 6.1 mm, a thickness of approximately 3.1 mm and a weight of approximately 0.08 g.(3) Benidipine Hydrochloride Tablets 4 mg: Each tablet contains 4 mg of benidipine hydrochloride, with a diameter of approximately 7.1 mm, a thickness of approximately 3.3 mm and a weight of approximately 0.13 g.(4) Benidipine Hydrochloride Tablets 8 mg: Each tablet contains 8 mg of benidipine hydrochloride, with a diameter of approximately 8.1 mm, a thickness of approximately 3.8 mm and a weight of approximately 0.20 g.(5) The surface of tablets of each specification is printed with exclusive identification codes (e.g., KH208, KH209, KH210), facilitating pharmaceutical traceability and medication safety verification.
Active Ingredient and Excipients
(1) Besides the active ingredient of benidipine hydrochloride.(2) The tablets also contain a variety of pharmaceutical excipients including lactose hydrate, hypromellose, polyethylene glycol 6000, titanium dioxide and yellow ferric oxide, so as to ensure the stability, palatability and appearance of the preparation.
Physicochemical Properties
(1) Benidipine Hydrochloride is a yellow crystalline powder, slightly soluble in water, and freely soluble in methanol and formic acid.(2) Its chemical structure is stable and not prone to decomposition at room temperature, making it suitable for the preparation of oral solid dosage forms.
Storage of Benidipine Hydrochloride (Coniel)
Storage Conditions
(1) This product should be stored at room temperature, protected from high temperature, moisture and direct sunlight.(2) Refrigeration is not required, and it should not be placed in places with significant fluctuations in temperature and humidity such as bathrooms and vehicles.
Validity Period
(1) The validity period is 3 years from the date of manufacture.(2) Do not use the product after the expiration date.
Precautions for Use
(1) After unsealing: If the tablet needs to be split for administration, the split portion should be taken as soon as possible, and the remaining part should be stored away from light to prevent degradation of the drug ingredients.
(2) Packaging instructions: This product is packed in PTP aluminum-plastic blisters. The tablet should be removed from the aluminum foil before administration and shall never be swallowed together with the aluminum foil, so as to avoid esophageal injury or perforation.
